Saudi Arabia Osteoporosis Drugs Market, By Type (Primary Osteoporosis & Secondary Osteoporosis), Drugs (Bisphosphonates, Monoclonal Antibodies, Hormone Therapy & Others), Drugs Type (Branded & Generic), Route of Administration (Injectable, Oral & Others), Gender (Female & Male), Age Group (Geriatrics, Adults & Pediatrics), End User (Hospitals, Specialty Clinics, Homecare & Others), Distribution Channel (Direct Tender, Retail Sales & Others) Industry Trends and Forecasts to 2029.
Saudi Arabia Osteoporosis Drugs Market Analysis and Insights
According to the International Osteoporosis Foundation (IOF), ‘osteoporosis, which means porous bone, is a disease in which the quality and density of bone are reduced. As bones become more fragile and porous, the risk of fracture is greatly increased. The loss of bone occurs progressively and silently. Often there are no symptoms until the first fracture occurs.
With age, some of the bone cells begin to dissolve bone matrix, the process is called resorption, while new bone cells deposit osteoid, and the process is called formation. This process is called as remodeling. For people with osteoporosis, bone loss outpaces the growth of new bone. Bones become brittle, porous and prone to fracture. Though osteoporosis fractures can occur in other bones also, but he most commonly osteoporosis fractures occurs at wrist, spine or the hip.
The different types of medications for osteoporosis are available in the market. The bisphosphonates are usually the first choice for treatment of osteoporosis. These includes Risedronate (Actonel), a weekly or monthly pill, Alendronate (Fosamax), a weekly pill, Zoledronic acid (Reclast), an annual IV infusion and Ibandronate (Boniva), a monthly pill or quarterly intravenous (IV) infusion.
Data Bridge Market Research analyses that the Saudi Arabia osteoporosis drugs market will grow at a CAGR of 2.9% during the forecast period of 2022 to 2029.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Pricing in USD
|
|
Segments Covered
|
Type (Primary Osteoporosis & Secondary Osteoporosis), Drugs (Bisphosphonates, Monoclonal Antibodies, Hormone Therapy & Others), Drugs Type (Branded & Generic), Route of Administration (Injectable, Oral & Others), Gender (Female & Male), Age Group (Geriatrics, Adults & Pediatrics), End User (Hospitals, Specialty Clinics, Homecare & Others), Distribution Channel (Direct Tender, Retail Sales & Others)
|
|
Countries Covered
|
Saudi Arabia
|
|
Market Players Covered
|
Eli Lilly and Company (U.S.), Novartis AG (Switzerland) , Amgen Inc. (U.S.), Tabuk pharmaceuticals (Saudi Arabia), SPIMACO (Saudi Arabia), Hikma Pharmaceuticals PLC (Jordan), Pfizer Inc. (U.S.) , Merck KGaA (Germany) , Apotex Inc. (Canada), ABIOGEN PHARMA S.p.A. (Italy), Sudair Pharma (Saudi Arabia), tadawipharma. (Saudi Arabia), Fresenius SE & Co. KGaA (Germany), Hayat Pharmaceutical Industries Co. PLC (Jordan), and SAJA Pharmaceuticals (Saudi Arabia)
|
Osteoporosis Drugs Market Dynamics
Drivers
- Rise in Prevalence of Osteoporosis
Osteoporosis is a disease of bone which progresses due to the less bone mineral density and bone mass or due to some variation in the quality or structure of bone. Osteoporosis could increase the risk of fractures leading to broken bones due to decreased bone strength.
For instance,
- According to the International Osteoporosis Foundation, the prevalence of low bone mass is higher in Middle East then in western countries. Though osteoporosis affects both males and females, females are likely to develop osteoporosis than men
- Rise in geriatric population
As the geriatric population increases, osteoporosis and bone disorders are also rising among the older population. The aging population would refer to orthopedic centers which would increase the demand for osteoporosis treatment and hence is expected to as driver for the growth of Saudi Arabia osteoporosis drugs market.
Opportunities
- Government Initiatives
The osteoporosis is often referred to as the “silent disease” as bone loss is painless and gradual, and there are usually no symptoms to indicate a person is developing osteoporosis. So government is taking initiative early secreening, diagnosis and treatment of disease in the country. Therefor, acting as opportunity for the growth of the market in coming years.
Restraints/Challenges
However, the side effects associated with osteoporosis drugs and high treatment cost will hamper the growth of the osteoporosis durgs market in Saudi Arabia. Additionally, slow progress in restructuring the healthcare system will further challenge the market in the forecast period mentioned above.
This osteoporosis durgs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on lab supplies market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Osteoporosis is a disease of bone which progresses due to the less bone mineral density and bone mass or due to some variation in the quality or structure of bone. According to the Ministry of Health of Saudi Arabia, in 2018, the prevalence of osteoporosis was 37% in the population above the age of 50 years.
According to the international journal of research in medical sciences, in 2014, 82% of Saudi women patients had vitamin D deficiency. Only 21% of women were exposed to sunlight, 58% of the women had low BMD, out of which 18% with osteoporosis and 40% with osteopenia.
Osteoporosis drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohot multivariate statistical model for forecasting the market in growth period.
Post COVID-19 Impact on Lab Supplies Market
The COVID-19 has negatively affected the market. Lockdowns and isolations during pandemic complicates the disease management and medication adherence. The lack of access to healthcare facilities for routine treatment and medication administration will further impact the market.
Recent Development
- In September 2021, Hikma Pharmaceuticals PLC announced that it has agreed to acquire Custopharm Inc. to grow the injectable and generic business segments of the company. Custopharm has received 13 US FDA approvals, with four first-to-market Abbreviated New Drug Application (ANDA) approvals - including one with Competitive Generic Therapy (CGT) designation - and one novel 505(b)(2) NDA approval. This acquisition helped the company to increase its product portfolio and to further grow the overall revenue of the company.
Saudi Arabia Osteoporosis Drugs Market Scope
The osteoporosis drugs market is categorized into eight notable segments based on type, drugs, drugs type, route of administration, gender, age group, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Primary Osteoporosis
- Secondary Osteoporosis.
On the basis of type, Saudi Arabia osteoporosis drugs market is segmented into primary osteoporosis and secondary osteoporosis.
Drugs
- Bisphosphonates
- Monoclonal Antibodies
- Hormone Therapy
- Others
On the basis of drugs, Saudi Arabia osteoporosis drugs market is segmented into bisphosphonates, monoclonal antibodies, hormone therapy and others.
Drugs Type
- Branded
- Generic
On the basis of drugs type, Saudi Arabia osteoporosis drugs market is segmented into branded and generic.
Route of Administration
- Injectable
- Oral
- Others
On the basis of route of administration, Saudi Arabia osteoporosis drugs market is segmented into injectable, oral and others.
Gender
- Female
- Male
On the basis of gender, Saudi Arabia osteoporosis drugs market is segmented into female and male.
Age Group
- Geriatrics
- Adults
- Pediatrics
On the basis of age group, Saudi Arabia osteoporosis drugs market is segmented into geriatrics, adults and pediatrics.
End User
- Hospitals
- Specialty Clinics
- Homecare
- Others
On the basis of end user, Saudi Arabia osteoporosis drugs market is segmented into hospitals, specialty clinics, homecare and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
On the basis of distribution channel, Saudi Arabia osteoporosis drugs market is segmented into direct tender, retail sales and others.
Pipeline Analysis
The pipeline analysis of osteoporosis drugs market includes various pipeline therapies such as Ibandronate, Risedronate Sodium, Ibandroante (Bonviva/Boniva), Strontium Ranelate. F. Hoffman-La Roche Ltd, Sanofi, Nycomed, Elly Lilly and Company and Nordic Biosciences A/S among others are involved in the development of potential drugs for the improvement of treatment of osteoporosis.
Competitive Landscape and Osteoporosis Drugs Market Share Analysis
The osteoporosis durgs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Saudi Arabia presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to osteoporosis durgs market.
Some of the major players operating in the Saudi Arabia osteoporosis drugs market are Eli Lilly and Company, Novartis AG, Amgen Inc., Tabuk pharmaceuticals, SPIMACO, Hikma Pharmaceuticals PLC, Pfizer Inc., Merck KGaA, Apotex Inc., ABIOGEN PHARMA S.p.A., Sudair Pharma, tadawipharma., Fresenius SE & Co. KGaA, Hayat Pharmaceutical Industries Co. PLC, and SAJA Pharmaceuticals among others.
SKU-